NCT05780801View on ClinicalTrials.gov

Sentinel Cohort REACT

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Multi-Drug Resistant Organism
Interventions
DRUG

Allogeneic Microbiota in Glycerol (10%) (AMG)

Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.

Trial Locations (1)

30030

Emory Long-Term Acute Care, Decatur

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Emory University

OTHER